A Phase 2 clinical trial led by Dr. Kristie Blum at Ohio State University Comprehensive Cancer Center revealed encouraging results for the therapeutic combination of rituximab and Velcade in patients with specific subtypes of non-Hodgkin’s lymphoma. Read the article: http://bit.ly/1MAol7i
